Sumitomo Mitsui Trust Group Inc. Trims Stock Position in Personalis, Inc. $PSNL

Sumitomo Mitsui Trust Group Inc. cut its position in Personalis, Inc. (NASDAQ:PSNL) by 6.6% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 484,270 shares of the company’s stock after selling 34,171 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned approximately 0.46% of Personalis worth $3,085,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd boosted its stake in shares of Personalis by 76.1% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock worth $27,000 after buying an additional 1,479 shares during the period. International Assets Investment Management LLC purchased a new stake in shares of Personalis in the fourth quarter valued at approximately $31,000. Legal & General Group Plc purchased a new stake in shares of Personalis during the 2nd quarter worth $30,000. BNP Paribas Financial Markets boosted its holdings in Personalis by 406.4% during the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after buying an additional 5,177 shares in the last quarter. Finally, AQR Capital Management LLC purchased a new stake in shares of Personalis during the 4th quarter worth approximately $82,000. Institutional investors and hedge funds own 61.91% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Christopher M. Hall sold 100,000 shares of the company’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $13.15, for a total transaction of $1,315,000.00. Following the completion of the transaction, the chief executive officer directly owned 235,986 shares of the company’s stock, valued at approximately $3,103,215.90. This represents a 29.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 51,251 shares of the company’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $13.18, for a total value of $675,488.18. Following the transaction, the chief financial officer owned 198,833 shares of the company’s stock, valued at approximately $2,620,618.94. The trade was a 20.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 435,032 shares of company stock valued at $5,599,929. 4.20% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

PSNL has been the topic of several recent research reports. TD Cowen reiterated a “buy” rating on shares of Personalis in a research report on Wednesday. Wall Street Zen cut Personalis from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. Morgan Stanley raised their target price on shares of Personalis from $9.00 to $13.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 9th. BTIG Research lowered their price target on Personalis from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Monday, May 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a research note on Tuesday, April 21st. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $11.67.

Personalis Trading Up 5.1%

PSNL stock opened at $15.79 on Thursday. The company has a market capitalization of $1.65 billion, a P/E ratio of -15.48 and a beta of 2.24. Personalis, Inc. has a twelve month low of $3.84 and a twelve month high of $16.15. The firm has a 50 day simple moving average of $10.56 and a 200-day simple moving average of $8.80.

Personalis (NASDAQ:PSNL) last released its earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.06). The company had revenue of $15.47 million during the quarter, compared to the consensus estimate of $14.48 million. Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%. On average, research analysts predict that Personalis, Inc. will post -1.07 EPS for the current year.

Personalis Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical?stage genomics company that develops and markets advanced next?generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T?cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno?oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in?depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.